Instylla

Instylla is a medical device company based in Bedford, Massachusetts, focused on developing advanced liquid embolic products for interventional radiology. Founded in 2017, the company is backed by prominent venture capital firms and aims to enhance embolization therapies for interventional oncology and peripheral hemostasis. The flagship product, the Embrace™ Hydrogel Embolic System, is designed for controlled and persistent embolization of hypervascular tumors and peripheral arteries up to 5mm in diameter. This system aims to improve patient outcomes by reducing procedure times and increasing technical confidence for healthcare professionals. Instylla's proprietary hydrogel technology supports its innovative approach to addressing clinical needs in the field. The leadership team at Instylla has extensive experience in medical device design and clinical affairs. The company primarily serves interventional radiologists and oncologists, providing advanced solutions for embolization procedures. Recently, the Embrace™ Hydrogel Embolic System received U.S. FDA premarket approval, marking a significant milestone for Instylla in the interventional radiology and oncology market.

• Employees 49
• Founded 2017
• Annual Revenue $8000000
• Total Funding $63535004